Vivani Medical Inc.
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Metabolic Diseases
Vivani Medical, Inc. is a clinical stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal™ technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address leading causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. Vivani's lead program, NPM-139 (semaglutide implant) is under development for chronic weight management and Vivani's pipeline represent the only miniature, subdermal GLP-1 implants under development today.
Company HQ City:
Alameda
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
August 30, 2022 (merger of Second Sight Medical Products, Inc. and Nano Precision Medical, Inc.)
Lead Product in Development:
NPM-139 (semaglutide implant)
CEO
Adam Mendelsohn, PhD
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
3
Exchange
Nasdaq
Ticker
VANI
When you expect your next catalyst update?
Mid-2026
What is your next catalyst (value inflection) update?
NPM-139 Phase 1 First Patient Dosed
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}